CPDC Celebrates Successful FDA Inspection!

August 23, 2019 CPDC
« 1 of 6 »

Hamilton, Ontario, August 16, 2019 – The Centre for Probe Development and Commercialization’s Senior Leadership Team took time on Friday afternoon to celebrate with their Hamilton staff on the McMaster University campus at the famous Willy Dog Hot Dog cart. Over 60 staff attended the lunch time event on a great summer day!  The event was held to show appreciation to our staff for the effort put into the preparation for CPDC’s FDA audit held in July 2019. Special treats were sent to our offsite locations in Toronto and Ottawa, as well as to the night shift staff in Hamilton, to ensure the whole company was included in the event.

CPDC’s President and CEO, Dr. Joe McCann commented at the event that “CPDC is committed to maintaining industry leading quality standards and implementing continued quality improvements. We are very grateful and appreciative of our staff who all embrace this approach and who put significant effort into the preparation for the audit.  We are extremely pleased to announce that no observations were received at the conclusion of the inspection.  CPDC extends its gratitude to our clients who supported us during the inspection.” CPDC is also inspected by Health Canada and has maintained a compliant rating since 2009.

About CPDC

The Centre for Probe Development and Commercialization (CPDC) is a private, not-for-profit company “Dedicated to improving patient’s lives by advancing drugs for the diagnosis and treatment of diseases.”  Created in 2008, with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and the Ontario Institute for Cancer Research (OICR), CPDC has become a global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals. With an established a pipeline of products and a robust and reliable manufacturing unit, CPDC supplies innovative diagnostic and therapeutic radiopharmaceuticals that are used daily in Canada and around the world. CPDC currently employs over 110 staff in Hamilton, Toronto and Ottawa. For more information about CPDC, please visit: www.imagingprobes.ca

Contacts

Centre for Probe Development and Commercialization

Angela Lauretani, 905 525-9140, ext. 21212

cpdc@imagingprobes.ca

More news from CPDC

Unleashing Canada’s Radiopharmaceutical Excellence. New Pan-Canadian Partnership Looks to Commercialize the Country’s Most Promising Radiopharmaceutical Innovations

The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) are pleased to announce they have formed a new collaboration, “The CPDC-adMare Radiopharmaceutical Initiative (CARI)” to bring their respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain a considerable global competitive advantage: radiopharmaceuticals. This

Isotopia Molecular Imaging and CPDC Announce Production Agreement for n.c.a. Lu-177

Hamilton, Ontario, September 8, 2020 – Isotopia Molecular Imaging and CPDC are pleased to announce that they have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer, including neuroendocrine tumors and prostate cancer.

CPDC Announces Appointment of Justyna Kelly as Permanent CEO

Hamilton, Ontario June 23, 2020 The Centre for Probe Development and Commercialization (CPDC) announced that its Board of Directors has appointed Justyna Kelly as Chief Executive Officer (CEO). The CEO appointment has taken effect on June 18, 2020. Justyna Kelly was appointed the role of interim CEO in December 2019. Mark Lundie, outgoing Chair of

For more information contact us at: